Butylated hydroxyanisole

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:15664432	IVR	10 mg/kg/day	10 mg/kg/day	Abnormal sperm morphology	Reproductive endocrine-mediated perturbations
	IVR	10 mg/kg/day	10 mg/kg/day	Decreased spleen weights	Immunological endocrine-mediated perturbations
	IVR	500 mg/kg/day	500 mg/kg/day	Increased weights of adrenal gland in offspring	Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Decreased weights of epididymis in offspring	Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Abnormal sperm morphology	Reproductive endocrine-mediated perturbations
	IVR	500 mg/kg/day	500 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Decreased testosterone levels	Reproductive endocrine-mediated perturbations
	IVR	500 mg/kg/day	500 mg/kg/day	Abnormal sperm morphology	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Decrease in T4 levels	Metabolic endocrine-mediated perturbations
	IVR	500 mg/kg/day	500 mg/kg/day	Alterations in vaginal opening of offspring	Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	500 mg/kg/day	500 mg/kg/day	Reduced sperm counts	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Changes in morphology of thyroid gland in offspring	Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations
	IVR	500 mg/kg/day	500 mg/kg/day	Decreased testosterone levels	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	500 mg/kg/day	500 mg/kg/day	Changes in morphology of thyroid gland in offspring	Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations
	IVR	100 mg/kg/day	100 mg/kg/day	Decreased spleen weights	Immunological endocrine-mediated perturbations
	IVR	500 mg/kg/day	500 mg/kg/day	Abnormal estrous cycles	Reproductive endocrine-mediated perturbations
	IVR	500 mg/kg/day	500 mg/kg/day	Decreased weights of vagina	Reproductive endocrine-medi
	IVR	500 mg/kg/day	500 mg/kg/day	Affects sexual behavior
	IVR	500 mg/kg/day	500 mg/kg/day	Increased weights of adrenal gland
	IVR	500 mg/kg/day	500 mg/kg/day	Decreased prostate weights
	IVR	500 mg/kg/day	500 mg/kg/day	Increased weights of thyroid gland
	IVR	500 mg/kg/day	500 mg/kg/day	Decrease in T4 levels
	IVR	500 mg/kg/day	500 mg/kg/day	Alterations in preputial separation
	IVR	500 mg/kg/day	500 mg/kg/day	Decreased spleen weights
	IVR	500 mg/kg/day	500 mg/kg/day	Affects sperm motility
PMID:16023279	IVR	250 mg/kg	250 mg/kg	Decreased uterine weights	Reproductive endocrine-mediated perturbations
	IVR	500 mg/kg	500 mg/kg	Decreased uterine weights	Reproductive endocrine-mediated perturbations
	IVR	100 mg/kg	100 mg/kg	Decreased uterine weights	Reproductive endocrine-mediated perturbations
	IVR	500 mg/kg	500 mg/kg	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	50 mg/kg	50 mg/kg	Decreased uterine weights	Reproductive endocrine-mediated perturbations
PMID:29236469	IVTH	0.0000000001 - 0.0001 M	0.000001 - 0.0001 M	Increased estradiol levels	Reproductive endocrine-mediated perturbations
	IVTH	0.0000000001 - 0.0001 M	0.000001 - 0.0001 M	Affects steroidogenesis	Reproductive endocrine-mediated perturbations
PMID:29460325	IVTH	0.00001 M	0.00001 M	Cancer phenotype	Endocrine-mediated cancer
	IVTH	0.0000001 M	0.0000001 M	Cancer phenotype	Endocrine-mediated cancer
	IVTH	0.0001 M	0.0001 M	Cancer phenotype	Endocrine-mediated cancer

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.